8 / 8
Page 39
Biomaterials Congress 2019
Materials Science and Nanotechnology | Volume 3
June 19-20, 2019 | Dublin, Ireland
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
BIOMATERIALS,
CELLULAR AND TISSUE ENGINEERING
3
rd
International Conference on
Mater Sci Nanotechnol 2019, Volume 3
DECELLULARISATION OF HEART VALVES
G Subramanyam
Narayana Medical Intuitions, India
H
eart failure is the end stage of heart disease and occurs when all compensatory mechanisms due to under-
lying heart disease are not maintaining the cardiac output. Valvular heart disease, ischemic heart disease,
hypertensive heart disease and cardiomyopathy in the elderly and congenital heart disease in the children
are well established factors of heart failure. A.C inhibitors, Diuretics, Beta-blocker, vasodilators and lanoxin are
mainstay of medical treatment. Cardiac transplantation with immune suppressants therapy is widely accepted
procedure for end stage cardiac failure that is with severe functional limitations and refractory to treatment
modalities. But cardiac transplantation is not accessible for majority of the patients.
Because of higher cost and lack of sufficient technical expertisation and non-availability of number of centers
alternative strategy is considered to solve the end stage heart failure with stem cell therapy. Live organ equiv-
alent which is biocompatible is still in the experimental stage. Tissue engineering of heart valves are used with
success. Decellularisation of heart valves and recellurisation of tissue engineered valves have shown promising
results. Whole cardiac extracellular matrix as a scaffold and seedling of pluripotent stem cells derived cardio-
myocytes after antigen removal by protein Solubilisation, sarcomeric disassembly preserved mechanical and
structural properties have a role in tissue engineering and stem cell therapy. Cardiac extra matrix scaffold with
stem cell recellurisation may be the answer in the future as an alternative to cardiac transplantation.